Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Fineline Cube Sep 9, 2026
Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Fineline Cube Sep 9, 2026
Company

Henlius Pharma’s 2022 Interim Revenue Jumps 103.5% on Biosimilar Sales and Licensing

Fineline Cube Aug 19, 2022

Shanghai Henlius Pharmaceutical Co., Ltd (HKG: 2696) reported RMB 1.29 billion (USD 189.4 million) in...

Company Deals

LongBio Pharma Raises Series A+ Funding to Advance Autoimmune Disease Drug Development

Fineline Cube Aug 19, 2022

LongBio Pharma, a Shanghai-based next-generation macromolecular antibody developer, has raised tens of millions of renminbi...

Company Drug

Fosun Kite’s Yescarta CAR-T Therapy Secures New Clinical Trial Approval in China

Fineline Cube Aug 19, 2022

Fosun Kite Biotechnology Co., Ltd, a joint venture between Shanghai Fosun Pharmaceutical (Group) Co., Ltd...

Company Deals

mProbe Raises Funds in Series B1 Round Led by AstraZeneca and CICC

Fineline Cube Aug 19, 2022

Zhejiang-based mProbe, a protein and metabolomic marker discovery technology-based platform company, has reportedly raised an...

Company Deals

Huahai Pharma to Manufacture Pfizer’s Paxlovid for China Market

Fineline Cube Aug 19, 2022

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has entered into a manufacturing and supply...

Company Drug

Recbio Completes Phase II Trial Enrollment for ReCOV COVID-19 Vaccine

Fineline Cube Aug 19, 2022

China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) announced the completion of enrollment...

Company Deals

Healsun Biopharm Raises USD 36.7 Million in Series B Financing for Antibody CDMO Expansion

Fineline Cube Aug 19, 2022

China-based Hangzhou Healsun Biopharm Co., Ltd, an antibody and recombinant Contract Development and Manufacturing Organization...

Company Drug

Sirnaomics Initiates Phase I/II Trial for STP705 in Facial Squamous Cell Carcinoma

Fineline Cube Aug 19, 2022

Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) announced the first subject systemic dosing in...

Policy / Regulatory

NHC, NDRC Issue Guidelines to Boost China’s Birth Rates with Reproductive Support Measures

Fineline Cube Aug 19, 2022

The National Health Commission (NHC) and National Development and Reform Commission (NDRC), along with multiple...

Company Deals

Biocytogen Pharmaceuticals Makes HKSE Debut with USD 70 Million IPO

Fineline Cube Aug 19, 2022

Sino-US contract research organization (CRO) Biocytogen Pharmaceuticals (Beijing) Co., Ltd has completed an initial public...

Company Drug

CSPC Pharmaceutical’s Mitoxantrone Liposome Approved for NMOSD Clinical Study

Fineline Cube Aug 19, 2022

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its mitoxantrone hydrochloride liposome has received...

Company Deals

Jemincare Licenses Oral Androgen Receptor Degrader to Roche’s Genentech

Fineline Cube Aug 18, 2022

China-based Jiangxi Jemincare Group has entered into a licensing agreement with Swiss giant Roche’s Genentech....

Company Drug R&D

Spinraza’s NRDL Inclusion Boosts SMA Patient Treatment in China

Fineline Cube Aug 18, 2022

The Meier Advocacy & Support Center for Spinal Muscular Atrophy (SMA) and the Shenzhen Research...

Policy / Regulatory

CDE Releases Draft Guidelines for RWE-Backed Drug Registration Applications

Fineline Cube Aug 18, 2022

The Center for Drug Evaluation (CDE) has released a notification regarding the “Real-World Evidence (RWE)-backed...

Drug

ICT’s GCC19CART Enters US Phase I Study for Colorectal Cancer

Fineline Cube Aug 18, 2022

Sino-US firm Innovative Cellular Therapeutics (ICT) announced the involvement of the first subject in a...

Drug

BRL Medicine’s BRL-101 Receives Clinical Trial Approval for Beta-Thalassemia

Fineline Cube Aug 18, 2022

Shanghai-based BRL Medicine Inc. has announced that it has received clinical trial approval from the...

Company Legal / IP

GenScript Biotech Sues Former CSO Fan Xiaohu for Trade Secret Infringement

Fineline Cube Aug 18, 2022

Hong Kong-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has sued its former...

Company Drug

Innovent Biologics Initiates Phase I Study of IBI311 for Thyroid-Associated Ophthalmopathy

Fineline Cube Aug 18, 2022

China-based biotech Innovent Biologics Inc. (HKG: 1801) announced that the first subject has been dosed...

Company Digital Hospital

Baidu Health’s Precision Matching Engine Powers Public Hospitals

Fineline Cube Aug 18, 2022

China Internet giant Baidu’s one-stop health management platform Baidu Health has updated the status of...

Company

WuXi Biologics’ Revenues Surge 63.5% in H1 2022 on Strong CRDMO Growth

Fineline Cube Aug 18, 2022

China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKEX: 2269) published its unaudited...

Posts pagination

1 … 687 688 689 … 718

Recent updates

  • BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices
  • CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation
  • Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030
  • Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins
  • China’s NHC Issues Eye Health Services Work Plan for 2026–2030 – Setting 2030 Targets on Cataract Surgery Rates, Ophthalmologist Workforce Density, and County‑Level Vision Care Capacity
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Company

Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030

Company Drug

Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.